-
1
-
-
79961199944
-
Hepatitis C virus infection in the USA: an estimate of true prevalence
-
PID: 21745274
-
Chak E, Talal AH, Sherman KE, Schiff ER, Saab S. Hepatitis C virus infection in the USA: an estimate of true prevalence. Liver Int. 2011;31:1090–1101.
-
(2011)
Liver Int
, vol.31
, pp. 1090-1101
-
-
Chak, E.1
Talal, A.H.2
Sherman, K.E.3
Schiff, E.R.4
Saab, S.5
-
2
-
-
84877755305
-
Hepatitis C in the United States
-
COI: 1:CAS:528:DC%2BC3sXnsl2gsro%3D, PID: 23675657
-
Holmberg SD, Spradling PR, Moorman AC, Denniston MM. Hepatitis C in the United States. N Engl J Med. 2013;368:1859–1861.
-
(2013)
N Engl J Med
, vol.368
, pp. 1859-1861
-
-
Holmberg, S.D.1
Spradling, P.R.2
Moorman, A.C.3
Denniston, M.M.4
-
3
-
-
33747797031
-
Treating viral hepatitis C: efficacy, side effects, and complications
-
COI: 1:CAS:528:DC%2BD28XhtVehurfE, PID: 16905701
-
Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut. 2006;55:1350–1359.
-
(2006)
Gut
, vol.55
, pp. 1350-1359
-
-
Manns, M.P.1
Wedemeyer, H.2
Cornberg, M.3
-
4
-
-
79957497436
-
A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C
-
PID: 21397729
-
Backus LI, Boothroyd DB, Phillips BR, Belperio P, Halloran J, Mole LA. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol. 2011;9(509–516):e1.
-
(2011)
Clin Gastroenterol Hepatol
, vol.9
, Issue.509-516
, pp. 1
-
-
Backus, L.I.1
Boothroyd, D.B.2
Phillips, B.R.3
Belperio, P.4
Halloran, J.5
Mole, L.A.6
-
5
-
-
65449136656
-
Diagnosis, management, and treatment of hepatitis C: an update
-
COI: 1:CAS:528:DC%2BD1MXkslWjs7o%3D, PID: 19330875
-
Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49:1335–1374.
-
(2009)
Hepatology
, vol.49
, pp. 1335-1374
-
-
Ghany, M.G.1
Strader, D.B.2
Thomas, D.L.3
Seeff, L.B.4
-
6
-
-
78049476361
-
A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin
-
COI: 1:CAS:528:DC%2BC3cXhtlKhurrJ, PID: 20637202
-
Swain MG, Lai MY, Shiffman ML, et al. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology. 2010;139:1593–1601.
-
(2010)
Gastroenterology
, vol.139
, pp. 1593-1601
-
-
Swain, M.G.1
Lai, M.Y.2
Shiffman, M.L.3
-
7
-
-
38449091418
-
Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis
-
PID: 18025443
-
Veldt BJ, Heathcote EJ, Wedemeyer H, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med. 2007;147:677–684.
-
(2007)
Ann Intern Med
, vol.147
, pp. 677-684
-
-
Veldt, B.J.1
Heathcote, E.J.2
Wedemeyer, H.3
-
8
-
-
0037179698
-
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection
-
COI: 1:CAS:528:DC%2BD38Xnt12rtb0%3D, PID: 12324553
-
Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975–982.
-
(2002)
N Engl J Med
, vol.347
, pp. 975-982
-
-
Fried, M.W.1
Shiffman, M.L.2
Reddy, K.R.3
-
9
-
-
68249154875
-
Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection
-
COI: 1:CAS:528:DC%2BD1MXps1Kjuro%3D, PID: 19625712
-
McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009;361:580–593.
-
(2009)
N Engl J Med
, vol.361
, pp. 580-593
-
-
McHutchison, J.G.1
Lawitz, E.J.2
Shiffman, M.L.3
-
10
-
-
84889646106
-
Comparative effectiveness of the hepatitis C virus protease inhibitors boceprevir and telaprevir in a large U.S. cohort
-
COI: 1:CAS:528:DC%2BC3sXhvVyjsr3K, PID: 24206566
-
Backus LI, Belperio PS, Shahoumian TA, Cheung R, Mole LA. Comparative effectiveness of the hepatitis C virus protease inhibitors boceprevir and telaprevir in a large U.S. cohort. Aliment Pharmacol Ther. 2014;39:93–103.
-
(2014)
Aliment Pharmacol Ther
, vol.39
, pp. 93-103
-
-
Backus, L.I.1
Belperio, P.S.2
Shahoumian, T.A.3
Cheung, R.4
Mole, L.A.5
-
11
-
-
79959438789
-
Telaprevir for previously untreated chronic hepatitis C virus infection
-
COI: 1:CAS:528:DC%2BC3MXotVCku7Y%3D, PID: 21696307
-
Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364:2405–2416.
-
(2011)
N Engl J Med
, vol.364
, pp. 2405-2416
-
-
Jacobson, I.M.1
McHutchison, J.G.2
Dusheiko, G.3
-
12
-
-
79953173221
-
Boceprevir for untreated chronic HCV genotype 1 infection
-
COI: 1:CAS:528:DC%2BC3MXkt1Chtrc%3D, PID: 21449783
-
Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1195–1206.
-
(2011)
N Engl J Med.
, vol.364
, pp. 1195-1206
-
-
Poordad, F.1
McCone, J.2
Bacon, B.R.3
-
13
-
-
80053339008
-
An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases
-
PID: 21898493
-
Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54:1433–1444.
-
(2011)
Hepatology
, vol.54
, pp. 1433-1444
-
-
Ghany, M.G.1
Nelson, D.R.2
Strader, D.B.3
Thomas, D.L.4
Seeff, L.B.5
-
14
-
-
84865291164
-
Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care
-
COI: 1:CAS:528:DC%2BC38Xht1GlsL%2FE, PID: 22647717
-
Pearlman BL. Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care. Lancet Infect Dis. 2012;12:717–728.
-
(2012)
Lancet Infect Dis
, vol.12
, pp. 717-728
-
-
Pearlman, B.L.1
-
15
-
-
84555170755
-
Boceprevir and telaprevir in the management of hepatitis C virus-infected patients
-
PID: 22156853
-
Butt AA, Kanwal F. Boceprevir and telaprevir in the management of hepatitis C virus-infected patients. Clin Infect Dis. 2012;54:96–104.
-
(2012)
Clin Infect Dis
, vol.54
, pp. 96-104
-
-
Butt, A.A.1
Kanwal, F.2
-
16
-
-
84877782905
-
Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies
-
PID: 23470616
-
Chen J, Florian J, Carter W, et al. Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies. Gastroenterology. 2013;144(1450–1455):e2.
-
(2013)
Gastroenterology
, vol.144
, Issue.1450-1455
, pp. 2
-
-
Chen, J.1
Florian, J.2
Carter, W.3
-
17
-
-
77950597305
-
Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin
-
COI: 1:CAS:528:DC%2BC3cXls1Cnt7c%3D, PID: 20069649
-
Martinot-Peignoux M, Stern C, Maylin S, et al. Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin. Hepatology. 2010;51:1122–1126.
-
(2010)
Hepatology
, vol.51
, pp. 1122-1126
-
-
Martinot-Peignoux, M.1
Stern, C.2
Maylin, S.3
-
18
-
-
72849119171
-
Rate and timing of hepatitis C virus relapse after a successful course of pegylated interferon plus ribavirin in HIV-infected and HIV-uninfected patients
-
COI: 1:CAS:528:DC%2BD1MXhsFSqu7%2FO, PID: 19814621
-
Medrano J, Barreiro P, Resino S, et al. Rate and timing of hepatitis C virus relapse after a successful course of pegylated interferon plus ribavirin in HIV-infected and HIV-uninfected patients. Clin Infect Dis. 2009;49:1397–1401.
-
(2009)
Clin Infect Dis
, vol.49
, pp. 1397-1401
-
-
Medrano, J.1
Barreiro, P.2
Resino, S.3
-
19
-
-
84912532123
-
Effectiveness of telaprevir and boceprevir triple therapy for patients with hepatitis C virus infection in a large integrated care setting
-
COI: 1:CAS:528:DC%2BC2cXhtlamsrnM, PID: 25102983
-
Price JC, Murphy RC, Shvachko VA, Pauly MP, Manos MM. Effectiveness of telaprevir and boceprevir triple therapy for patients with hepatitis C virus infection in a large integrated care setting. Dig Dis Sci. 2014;59:3043–3052.
-
(2014)
Dig Dis Sci
, vol.59
, pp. 3043-3052
-
-
Price, J.C.1
Murphy, R.C.2
Shvachko, V.A.3
Pauly, M.P.4
Manos, M.M.5
-
20
-
-
84879237873
-
Health-related quality of life in genotype 1 treatment-naive chronic hepatitis C patients receiving telaprevir combination treatment in the ADVANCE study
-
COI: 1:CAS:528:DC%2BC3sXht1art73K, PID: 23725204
-
Vera-Llonch M, Martin M, Aggarwal J, et al. Health-related quality of life in genotype 1 treatment-naive chronic hepatitis C patients receiving telaprevir combination treatment in the ADVANCE study. Aliment Pharmacol Ther. 2013;38:124–133.
-
(2013)
Aliment Pharmacol Ther
, vol.38
, pp. 124-133
-
-
Vera-Llonch, M.1
Martin, M.2
Aggarwal, J.3
-
21
-
-
84904132795
-
The Comparative clinical effectiveness and value of simeprevir and sofosbuvir for chronic hepatitis C virus infection
-
PID: 24798321
-
Ollendorf DA, Tice JA, Pearson SD. The Comparative clinical effectiveness and value of simeprevir and sofosbuvir for chronic hepatitis C virus infection. JAMA Intern Med. 2014;174:1170–1171.
-
(2014)
JAMA Intern Med.
, vol.174
, pp. 1170-1171
-
-
Ollendorf, D.A.1
Tice, J.A.2
Pearson, S.D.3
-
22
-
-
79953176289
-
Boceprevir for previously treated chronic HCV genotype 1 infection
-
COI: 1:CAS:528:DC%2BC3MXkt1Cht7k%3D, PID: 21449784
-
Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1207–1217.
-
(2011)
N Engl J Med
, vol.364
, pp. 1207-1217
-
-
Bacon, B.R.1
Gordon, S.C.2
Lawitz, E.3
-
23
-
-
79959381354
-
Telaprevir for retreatment of HCV infection
-
COI: 1:CAS:528:DC%2BC3MXotVCrsrg%3D, PID: 21696308
-
Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011;364:2417–2428.
-
(2011)
N Engl J Med
, vol.364
, pp. 2417-2428
-
-
Zeuzem, S.1
Andreone, P.2
Pol, S.3
|